887. Implementation of Long-acting Injectable Cabotegravir/Rilpivirine for HIV-1 Treatment at a Ryan White-funded Clinic in the U.S. South

BACKGROUND: In January 2021, the first ever long-acting injectable (LAI) antiretroviral therapy (ART), cabotegravir/rilpivirine (CAB/RPV), was approved for maintenance HIV-1 treatment in select patients with virologic suppression. LAI-ART has the potential to improve ART adherence, reduce HIV stigma...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Lauren F, Corbin-Johnson, Della, Asrat, Meron, Rankins, Tonya, Harrison, Latoya, Condra, Alton, Sumitani, Jeri, Smith, Bradley L, Armstrong, Wendy, Colasanti, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644083/
http://dx.doi.org/10.1093/ofid/ofab466.1082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644083/
http://dx.doi.org/10.1093/ofid/ofab466.1082

Ejemplares similares